Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flecainide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.93 |
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.93 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.93 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.93 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.93 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.93 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.93 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.93 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flecainide SCHEMBL308966 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNANPSR1PMP22CYP1A2 | |
| Flecainide SCHEMBL9614368 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNANPSR1PMP22CYP1A2 | |
| Flecainide SCHEMBL14970 | 0.96 | CYP1A2 (1.00) | SMN1; SMN2LMNANPSR1PMP22CYP1A2 | |
| Flecainide SCHEMBL29385957 | 0.96 | CYP1A2 (1.00) | SMN1; SMN2LMNANPSR1PMP22CYP1A2 | |
| Flecainide SCHEMBL17799127 | 0.96 | CYP1A2 (1.00) | SMN1; SMN2LMNANPSR1PMP22CYP1A2 | |
| (R)-Flecainide SCHEMBL14971 | 0.96 | CYP1A2 (1.00) | SMN1; SMN2LMNANPSR1PMP22CYP1A2 | |
| Acetic Acid SCHEMBL10469403 | 0.95 | SMN1; SMN2 (0.91) | SMN1; SMN2LMNANPSR1PMP22CYP1A2 | |
| Acetic Acid SCHEMBL10468143 | 0.95 | SMN1; SMN2 (0.91) | SMN1; SMN2LMNANPSR1PMP22CYP1A2 | |
| Flecainide SCHEMBL5569654 | 0.95 | CYP1A2 (0.98) | SMN1; SMN2LMNANPSR1PMP22CYP1A2 | |
| Flecainide SCHEMBL5569649 | 0.95 | CYP1A2 (0.98) | SMN1; SMN2LMNANPSR1PMP22CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2646 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12576074-B2 | Kits and methods for induction of cardioversion in subjects with atrial arrhythmias | INCARDA THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12576073-B2 | Antiarrhythmic formulation | INCARDA THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20250332152-A1 | INHALED THERAPY FOR CARDIAC ARRHYTHMIA | INCARDA THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | claimed |
| WO-2025217305-A1 | DEVICES, KITS, AND METHODS FOR DELIVERING MEDICATION VIA THE LUNGS | INCARDA THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| EP-3768378-B1 | A NOVEL METHOD TO SLOW VENTRICULAR RATE | INCARDA THERAPEUTICS INC (US) | 2025-08-06 | — | — | EP | claimed |
| CN-119453115-A | Method for constructing epilepsy animal model and medicine obtained by screening epilepsy animal model and used for treating epilepsy | 中国科学院重庆绿色智能技术研究院 | 2025-02-18 | — | — | CN | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| EP-4444417-A1 | INHALED THERAPY FOR CARDIAC ARRHYTHMIA | InCarda Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| WO-2007112581-A1 | CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT | ODIDI ISA (CA) | 2007-10-11 | — | — | WO | claimed |
| US-20040220409-A1 | Flecainide synthesis | MCDANIEL WILLIAM C | 2004-11-04 | — | — | US | claimed |
| US-20030032835-A1 | Antiarrhythmia agents | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.P.A (IT) | 2003-02-13 | — | — | US | claimed |
| EP-1283201-A1 | Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidyl-methyl)-benzamide (flecanide) | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. (IT) | 2003-02-12 | — | — | EP | claimed |
| WO-2002066413-A1 | FLECAINIDE SYNTHESIS | NARCHEM CORPORATION (US) | 2002-08-29 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0371683-B1 | CONTROLLED RELEASE FLECAINIDE ACETATE FORMULATION | RIKER LABORATORIES, INC. (US) | 1993-04-21 | — | — | EP | claimed |
| US-4938966-A | Controlled release flecainide acetate formulation | RIKER LABORATORIES, INC. (US) | 1990-07-03 | — | — | US | claimed |
| EP-0371683-A1 | Controlled release flecainide acetate formulation | RIKER LABORATORIES, INC. (US) | 1990-06-06 | — | — | EP | claimed |